Sana M Salih1. 1. Department of Obstetrics and Gynecology, University of Wisconsin, Madison, Wisconsin 53791, USA. salih@wisc.edu
Abstract
OBJECTIVE: To protect granulosa cells from chemotherapy-induced toxicity by retrovirus-mediated multidrug resistance (MDR1) gene transfection. DESIGN: Laboratory study. SETTING: Academic research laboratory in a university hospital. PATIENT(S): None. INTERVENTION(S): KK15 immortalized murine granulosa cell line transiently transduced with sf91m3 retrovirus vector carrying MDR1 complementary DNA that encodes P-glycoprtoein (P-gp); transduced cells selected with colchicine and treated with doxorubicin or paclitaxel for 24-72 hours; expression and function of MDR1 and the messenger RNA (mRNA) expression of selected steroidogenesis enzymes evaluated by flow cytometry, cell viability assays, Western blot, and reverse-transcriptase polymerase chain reaction (RT-PCR). MAIN OUTCOME MEASURE(S): Viability of sf91m3-transduced KK15 cells after treatment with doxorubicin and paclitaxel. RESULT(S): The sf91m3-transduced KK15 demonstrated high expression of biologically active MDR1, as shown by flow cytometry analysis and immunoblotting using P-gp monoclonal antibody and Rhodamine 123 efflux assays. The sf91m3-transduced KK15 exhibited statistically significant resistance to toxicity of 10 μM paclitaxel. The MDR1-transduced KK15 cells were also protected from doxorubicin toxicity (10 nM to 2.5 μM), as shown by cell viability assay. Both flow cytometry and cell viability assays showed that the protection of KK15 from doxorubicin toxicity was lost at 5 μM of doxorubicin; equivalent to 500 times LD50. The sf91m3-transduced KK15 showed normal mRNA expression of a panel of selected steroidogenesis enzymes. CONCLUSION(S): Retroviral gene delivery of human MDR1 inhibited chemotherapy-induced granulosa cell toxicity and offered chemoprotection in an in vitro model.
OBJECTIVE: To protect granulosa cells from chemotherapy-induced toxicity by retrovirus-mediated multidrug resistance (MDR1) gene transfection. DESIGN: Laboratory study. SETTING: Academic research laboratory in a university hospital. PATIENT(S): None. INTERVENTION(S): KK15 immortalized murine granulosa cell line transiently transduced with sf91m3 retrovirus vector carrying MDR1 complementary DNA that encodes P-glycoprtoein (P-gp); transduced cells selected with colchicine and treated with doxorubicin or paclitaxel for 24-72 hours; expression and function of MDR1 and the messenger RNA (mRNA) expression of selected steroidogenesis enzymes evaluated by flow cytometry, cell viability assays, Western blot, and reverse-transcriptase polymerase chain reaction (RT-PCR). MAIN OUTCOME MEASURE(S): Viability of sf91m3-transduced KK15 cells after treatment with doxorubicin and paclitaxel. RESULT(S): The sf91m3-transduced KK15 demonstrated high expression of biologically active MDR1, as shown by flow cytometry analysis and immunoblotting using P-gp monoclonal antibody and Rhodamine 123 efflux assays. The sf91m3-transduced KK15 exhibited statistically significant resistance to toxicity of 10 μM paclitaxel. The MDR1-transduced KK15 cells were also protected from doxorubicintoxicity (10 nM to 2.5 μM), as shown by cell viability assay. Both flow cytometry and cell viability assays showed that the protection of KK15 from doxorubicintoxicity was lost at 5 μM of doxorubicin; equivalent to 500 times LD50. The sf91m3-transduced KK15 showed normal mRNA expression of a panel of selected steroidogenesis enzymes. CONCLUSION(S): Retroviral gene delivery of humanMDR1 inhibited chemotherapy-induced granulosa cell toxicity and offered chemoprotection in an in vitro model.
Authors: Erin R Lepper; Kees Nooter; Jaap Verweij; Milin R Acharya; William D Figg; Alex Sparreboom Journal: Pharmacogenomics Date: 2005-03 Impact factor: 2.533
Authors: Hayley M McDaid; Lluis Lopez-Barcons; Aaron Grossman; Marie Lia; Steven Keller; Román Pérez-Soler; Susan Band Horwitz Journal: Cancer Res Date: 2005-04-01 Impact factor: 12.701
Authors: Jean-Philippe Annereau; Gergely Szakács; Charles J Tucker; Angela Arciello; Carol Cardarelli; Jennifer Collins; Sherry Grissom; Barry R Zeeberg; William Reinhold; John N Weinstein; Yves Pommier; Richard S Paules; Michael M Gottesman Journal: Mol Pharmacol Date: 2004-09-01 Impact factor: 4.436
Authors: Gloria I Perez; Andrea Jurisicova; Lisa Wise; Tatiana Lipina; Marijana Kanisek; Allison Bechard; Yasushi Takai; Patricia Hunt; John Roder; Marc Grynpas; Jonathan L Tilly Journal: Proc Natl Acad Sci U S A Date: 2007-03-08 Impact factor: 11.205
Authors: N Spears; F Lopes; A Stefansdottir; V Rossi; M De Felici; R A Anderson; F G Klinger Journal: Hum Reprod Update Date: 2019-11-05 Impact factor: 15.610